Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abandon, additionalVeraTag, adjudication, Akt, Allan, andHERmark, andSelzentry, assessedHERmark, auction, Avastin, barred, begun, bevacizumab, binding, budget, budgetary, byHERmark, CEO, christine, chromogenic, CISH, clarify, climate, cognizable, cohort, Combivir, commercializeHERmark, comparison, concurrently, construct, contrast, corroborated, delisted, Delisting, discordance, downstream, downturn, driven, efavirenz, endpoint, equivocal, evaluateHERmark, excessively, expenditure, frequently, FSP, fundamental, futureVeraTag, Genentech, hereto, Hershey, heterodimer, hierarchy, homodimerization, inaccuracy, includingHERmark, indicatesHERmark, instability, invicriviroc, jointly, Kaiser, Lipton, load, log, marker, Mayo, metastasized, neck, orderingHERmark, ordinary, ourHERmarkBreast, paclitaxel, Permanente, PhenoSenseGT, pleaded, predefined, prime, proceeding, Professor, properly, proteolytically, pure, radical, reinvest, reinvested, retroactively, RNA, Robust, SABC, salary, shown, suspended, Sustiva, thatSelzentry, theSelzentry, trastuzumab, tropic, truncated, UK, Underwriter, undetectable, undistributed, University, unresolved, unstable, unsuccessful, upcoming, upper, version, week, WhileHERmark, white, withHERmark, withholding, worse, zone
Removed:
accelerating, accrue, acted, Aetna, affiliated, aide, aim, amounting, analyze, assembly, attacked, attempt, background, backlog, baruch, begin, Blue, bore, broadening, complaint, compound, comprising, continuum, discipline, display, emphasized, encountered, endorsed, enzyme, Epidermal, eTag, expiring, feel, finance, Florida, GlaxoSmithKline, HAART, hearing, hire, hired, Humana, importance, incorporate, installed, investigation, Jersey, Johnson, lacking, launch, led, maturation, mechanism, monitor, mutational, online, outlining, positioned, predictive, Prioritize, productivity, professional, profile, promising, proportion, prove, recruitment, recurrence, reflecting, relocated, relying, request, restricted, revaluation, reviewing, rule, run, separation, Shield, smaller, Specialty, speed, sustain, unconditional, variable, warrant
Filing tables
Filing exhibits
- 10-K Annual report
- 10.4 Second Amended and Restated Employment Agreement
- 10.8 Form of Executive Severance Benefits Agreement
- 10.39 Summary of Non-employee Director Compensation
- 21.1 List of Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
Related press release
Monogram Biosciences similar filings
Filing view
External links
EXHIBIT 10.39
SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION
Beginning in 2007 and until further notice, each of the non-employee directors of Monogram Biosciences, Inc. shall receive an annual retainer of $20,000, paid in equal quarterly installments, a fee of $2,000 for each Board of Directors meeting attended in person, a fee of $500 for each Board of Directors meeting attended by phone and a fee of $500 for each committee meeting attended by committee members. In addition, the chair of the Audit Committee will receive an annual retainer of $10,000 and the chair of the Compensation Committee will receive an annual retainer of $5,000.